Literature DB >> 16844094

Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis.

Avril Pereira1, Brian Dean.   

Abstract

Clozapine, an atypical antipsychotic drug effective in treatment of refractory schizophrenia causes potentially life-threatening agranulocytosis. The drug undergoes bioactivation to a toxic, chemically reactive intermediate with capacity to target stromal cells, central components of the bone marrow microenvironment implicated in neutrophil development. To identify possible mechanisms underpinning disruption of stroma as a site of drug bioactivation, toxicity was induced in vitro. Therefore metabolite generation procedures utilizing HOCl or HRP-H(2)O(2) as primary components involved in clozapine metabolism were adapted for stromal culture and coupled with viability determinations. Drug oxidation by HOCl was less toxic to stromal cells than HRP-H(2)O(2) based methods. More specifically, clozapine bioactivation by HRP-H(2)O(2) caused dose-dependent inhibition of stromal viability at therapeutically relevant concentrations. Differences in susceptibility of HAS303 and LP101 cells to the clozapine nitrenium ion were also evident. Stromal cell death was attributed to clozapine in the presence of a complete metabolising system comprising HRP and H(2)O(2). In the absence of a complete metabolising system clozapine was not cytotoxic. For LP101 cells, drug plus HRP (minus H(2)O(2)) also induced toxicity. Importantly, other antipsychotic drugs including risperidone, olanzapine and haloperidol when bioactivated, were not cytotoxic, indicating system specificity for clozapine. Exogenous GSH, N-acetylcysteine, l-ascorbic acid, catalase, and sodium azide afforded protection to cells whereas S-methylGSH, GSSG, ketoprofen and proadifen did not. Thus functional data derived from the in vitro stromal system defined in these studies may enable further investigation of the mechanisms subserving stromal impairment in clozapine-induced agranulocytosis and direct attention to improved methods for its prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844094     DOI: 10.1016/j.bcp.2006.06.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

2.  Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar.

Authors:  Angélica Aparecida da Costa Güllich; Ritiéle Pinto Coelho; Bruna Cocco Pilar; Deise Jaqueline Ströher; Leandro Alex Sander Leal Galarça; Simone Machado Vieira; Jacqueline da Costa Escobar Piccoli; Sandra Elisa Haas; Vanusa Manfredini
Journal:  Metab Brain Dis       Date:  2014-10-09       Impact factor: 3.584

Review 3.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

4.  Clozapine treatment of patients with refractory schizophrenia, concurrent dengue infection and hematological abnormalities: three case reports.

Authors:  Emerson Arcoverde Nunes; Tatiana M N Rezende; Silvio L Morais; José A S Crippa; Serdar M Dursun; Glen B Baker; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2013-04

5.  Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

Authors:  S E Legge; M L Hamshere; S Ripke; A F Pardinas; J I Goldstein; E Rees; A L Richards; G Leonenko; L F Jorskog; K D Chambert; D A Collier; G Genovese; I Giegling; P Holmans; A Jonasdottir; G Kirov; S A McCarroll; J H MacCabe; K Mantripragada; J L Moran; B M Neale; H Stefansson; D Rujescu; M J Daly; P F Sullivan; M J Owen; M C O'Donovan; J T R Walters
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

6.  Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia.

Authors:  Jessica Foster; John Lally; Victoria Bell; Sukhi Shergill
Journal:  BJPsych Open       Date:  2017-02-09

7.  Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Authors:  Sophie E Legge; James Tr Walters
Journal:  Pharmacogenomics       Date:  2019-02-15       Impact factor: 2.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.